MARKET

SLDB

SLDB

Solid Bioscience
NASDAQ
6.84
-0.16
-2.29%
After Hours: 6.84 0 0.00% 16:10 11/13 EST
OPEN
7.00
PREV CLOSE
7.00
HIGH
7.05
LOW
6.57
VOLUME
975.45K
TURNOVER
--
52 WEEK HIGH
11.45
52 WEEK LOW
4.005
MARKET CAP
763.42M
P/E (TTM)
-3.8418
1D
5D
1M
3M
1Y
5Y
1D
Solid Biosciences (SLDB) Gets a Buy from J.P. Morgan
TipRanks · 1d ago
Circio Enters Research Collaboration With Solid Biosciences To Evaluate Combining CircVec Generation 5 Construct With POLARIS-101 AAV Capsid For Genetic Heart Disease Gene Therapy
Benzinga · 2d ago
William Blair Assumes Solid Biosciences at Outperform
Benzinga · 4d ago
Solid Biosciences a new Outperform at William Blair on Duchenne asset
Seeking Alpha · 4d ago
Solid Biosciences assumed with an Outperform at William Blair
TipRanks · 4d ago
Weekly Report: what happened at SLDB last week (1102-1106)?
Weekly Report · 4d ago
Solid Biosciences (SLDB) Gets a Buy from RBC Capital
TipRanks · 11/05 14:36
Leerink Partners Sticks to Their Buy Rating for Solid Biosciences (SLDB)
TipRanks · 11/05 14:29
More
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Webull offers Solid Biosciences Inc stock information, including NASDAQ: SLDB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLDB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLDB stock methods without spending real money on the virtual paper trading platform.